ICI Pharma's Nolvadex (tamoxifen)
ICI Pharma's Nolvadex (tamoxifen): Anti-estrogen drug receives supplemental approval for use in treating breast cancer in premenopausal women, as alternative to mastectomy. The oral hormone product is already indicated as a treatment for postmenopausal breast cancer and for use either alone or in combination with other anticancer agents following surgery in postmenopausal node-positive patients. The company estimates the U.S. patient population for the new indication at 14,000: 5,000 women who have advanced disease at diagnosis and 9,000 women with recurring disease.
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.